2025 · 1st Quarter (Jan 1 - Mar 31)

BRIDGEBIO PHARMA, INC.

Filed by BRIDGEBIO PHARMA, INC..

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: Apr 18, 2025
Income: Not reported
Expenses: $320,000.00
Registrant: BRIDGEBIO PHARMA, INC.
Client: BRIDGEBIO PHARMA, INC.
Filing UUID: 9187f107-ea43-4668-b9a5-0b3ab4cc6f69
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Give Kids a Chance Act of 2025 - H.R. 1262; S. 932 Orphan drug policies Scientific EXPERT Act of 2024 - H.R.1532; S. 822 Cameron's Law - H.R. 1414 FY25 Full Year Continuing Appropriations and Extensions Act - H.R. 1968

Literal federal measure citations: H.R. 1262, S. 932, H.R.1532, S. 822, H.R. 1414, H.R. 1968

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.